US EditionGSK forecasts slower sales growth in 2026
GSK's 2025 profit rose on 17% specialty medicines sales growth to £13.5 billion, led by HIV and respiratory drugs, with 7–9% profit rise forecast for 2026.
- On Wednesday, GSK reported 2025 results showing a sharp profit rise but warned of slower sales growth in fiscal 2026, citing declines in vaccines and medicines.
- Driven by specialty medicines, including strong HIV, respiratory and oncology sales, GSK's profit growth in 2025 was aided by settling Zantac litigation and factoring agreed US price cuts for 2026 guidance.
- Figures show revenue rose 4% to 32.7 billion and profit after tax more than doubled to 5.7 billion, with shares climbing near six percent on the London Stock Exchange.
- Miels told journalists the company is in 'very good shape' and will speed simplification as part of management action, while GSK announced plans to invest $30 billion in the United States over five years.
- Soon after taking over as CEO, Miels announced the $2.2 billion RAPT Therapeutics acquisition, emphasized UK commitment with 10,000 employees and �1.5 billion R&D spend, and focused on AI and technology.
65 Articles
65 Articles
InsideNoVA.com
GSK boosted by specialty drugs, end to Zantac fallout
British pharmaceutical group GSK reported Wednesday a sharp rise in annual net profit, boosted by strong sales of HIV, respiratory and cancer treatments as it recovered from costly US lawsuits over its Zantac heartburn treatment.
Luke Miels has to replace several sales agents. Vaccine fatigue creates new problems for the pharmaceutical company GSK. Analysts speculate about a savings program.
British pharmaceutical company GlaxoSmithKline (GSK) ended 2025 with a significant increase in net profit. It more than doubled from 2.6 billion pounds (3.01 billion euros) to 5.7 billion pounds (6.61 billion euros). Revenue increased by four percent to 32.7 billion pounds (37.6 billion euros).
New Hamburg independent
ParrySound.comFirstService Reports Fourth Quarter and Full Year Results
Delivers Strong Consolidated Annual Earnings
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
